Pfizer, Mylan say COVID-19 delays will postpone their Viatris merger

With the novel coronavirus pandemic continuing to hamstring operations, U.S. regulators have warned that major corporate transaction reviews could be held up. Now, thanks to those COVID-19 delays, a generics megamerger between Pfizer’s Upjohn and Mylan has been postponed until the back half of the year.

Leave a Reply

Your email address will not be published. Required fields are marked *